Trial Profile
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms STREAM
- 23 Mar 2023 Planned End Date changed from 1 Nov 2022 to 1 Nov 2024.
- 23 Mar 2023 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2024.
- 02 Jul 2022 Primary endpoint (the rate of evaluable patients alive and not progressed at 6 months) has not been met, as per results presented at the 24th World Congress on Gastrointestinal Cancer.